Alzheimer's Society of Ontario calls for immediate systemic investment to support access to newly approved dementia treatments
TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — The Alzheimer's Society of Ontario welcomes the approval of Lekanemab by Health Canada. This is a historic step forward in the treatment of Alzheimer's disease, and the Alzheimer's Society of Ontario appreciates the federal government's diligence in working to expand care options for people living with dementia. This milestone represents significant progress and new hope for individuals and families affected by Alzheimer's disease.
Although Lecanemab is not a cure, it is the first drug approved in Canada that targets the underlying biology of Alzheimer's disease and may slow the rate of cognitive decline. Lecanemab is approved for use in early stages of the disease and must be administered with close monitoring to manage risks. According to the Canadian Drug Agency's 2025 System Readiness Report, access to timely diagnosis, MRI capabilities and responsive public support such as the Alzheimer Society of Ontario's First Link program are important components needed to meet future demand for treatment.
“This approval gives families hope, but that hope must be backed by action,” said Kathy Barrick, CEO of the Alzheimer's Society of Ontario. “The Ontario government must invest in diagnostic and MRI capabilities while strengthening community support to ensure equitable access for all who can benefit from these treatments.”
The Ontario Dementia Care Alliance, a group of dementia experts representing the entire health care continuum, also called on the government to take coordinated action to ensure the system is ready for disease-modifying therapies. “The Dementia Care Alliance of Ontario is calling on the provincial government to make dementia an urgent health care priority by investing now in the infrastructure and support needed to implement disease-modifying treatments like lecanemab,” said Dr. Jenny Ingram, Chair of the Dementia Care Alliance of Ontario. “We have developed cost guidelines to prepare for this major shift in disease management. We are committed to working with the government to make these recommendations a reality.”
Health Canada's approval of Lekanemab is an important first step, but it does not guarantee that government drug plans will cover the treatment. The next step is for Lecanemab to be reviewed by the Canadian Drug Agency to provide guidance on public coverage, and provinces negotiate pricing with drugmaker Eisai Canada.
“This announcement reminds us that progress is possible and that persistence in research and innovation can lead to life-changing results,” Barrick said. “While this new therapy is not right for everyone, it represents a critical step forward—and the government has an opportunity to invest in the health system capacity needed for a dementia-ready Ontario.”
The Alzheimer's Society of Ontario remains committed to protecting a dementia-ready future while providing timely support for people living with dementia and their care partners today.
For more information, contact Adam Morrison, Senior Director of Public Policy and Partnerships, Alzheimer's Society of Ontario – 647-521-1624 | [email protected]
